PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27567806-5	2016	We found that imatinib reduces Abeta-oligomers in plasma, which correlates with a reduction of AD brain features such as plaques and oligomers accumulation, neuroinflammation, and cognitive deficits.	Imatinib Mesylate	14-22	amyloid beta (A4) precursor protein	Mus musculus	31-36	
27565738-6	2016	Indeed, we found that levels of the Abeta oligomers and the carboxy-terminal fragment betaCTF were decreased when the cells were treated with Imatinib and upon shRNA-mediated c-Abl knockdown.	Imatinib Mesylate	142-150	amyloid beta (A4) precursor protein	Mus musculus	36-41	
23209290-7	2013	In subsequent cellular studies with imatinib, a kinase inhibitor that reportedly prevents the interaction of GSAP with the C-terminal fragment of amyloid precursor protein, a concentration-dependent decrease in amyloid-beta levels was observed.	Imatinib Mesylate	36-44	amyloid beta (A4) precursor protein	Mus musculus	146-171	
24662099-9	2014	In vitro studies confirmed that Imatinib prevents Abeta formation by modulating gamma-secretase activity and GSAP levels.	Imatinib Mesylate	32-40	amyloid beta (A4) precursor protein	Mus musculus	50-55	
14523244-4	2003	In addition, the Abl kinase inhibitor imatinib mesylate (Gleevec, or STI571), which targets the ATP-binding site of Abl and several other tyrosine kinases, potently reduces Abeta production in the N2a cell-free system and in intact N2a cells.	Imatinib Mesylate	38-55	amyloid beta (A4) precursor protein	Mus musculus	173-178	
14523244-4	2003	In addition, the Abl kinase inhibitor imatinib mesylate (Gleevec, or STI571), which targets the ATP-binding site of Abl and several other tyrosine kinases, potently reduces Abeta production in the N2a cell-free system and in intact N2a cells.	Imatinib Mesylate	69-75	amyloid beta (A4) precursor protein	Mus musculus	173-178	
14523244-5	2003	Both STI571 and a related compound, inhibitor 2, also reduce Abeta production in rat primary neuronal cultures and in vivo in guinea pig brain.	Imatinib Mesylate	5-11	amyloid beta (A4) precursor protein	Mus musculus	61-66	
14523244-7	2003	Furthermore, production of Abeta and its inhibition by STI571 were demonstrated to occur to similar extents in both Abl-/- and WT mouse fibroblasts, indicating that the effect of STI571 on Abeta production does not involve Abl kinase.	Imatinib Mesylate	179-185	amyloid beta (A4) precursor protein	Mus musculus	27-32	
14523244-7	2003	Furthermore, production of Abeta and its inhibition by STI571 were demonstrated to occur to similar extents in both Abl-/- and WT mouse fibroblasts, indicating that the effect of STI571 on Abeta production does not involve Abl kinase.	Imatinib Mesylate	179-185	amyloid beta (A4) precursor protein	Mus musculus	189-194	
14523244-8	2003	The efficacy of STI571 in reducing Abeta without affecting Notch-1 cleavage may prove useful as a basis for developing novel therapies for Alzheimer"s disease.	Imatinib Mesylate	16-22	amyloid beta (A4) precursor protein	Mus musculus	35-40	
34985875-6	2022	The sensor was successfully applied to quantify c-Abl activity in the brain tissue of AD transgenic mice, and the interaction between c-Abl and Abeta in AD mice was explored by administering the c-Abl inhibitor (imatinib) and the agonist (DPH).	Imatinib Mesylate	212-220	amyloid beta (A4) precursor protein	Mus musculus	144-149	
30873837-1	2019	Imatinib mesylate, 1a, inhibits production of beta-amyloid (Abeta) peptides both in cells and in animal models.	Imatinib Mesylate	0-17	amyloid beta (A4) precursor protein	Mus musculus	60-65